

support public health activities for refugees, immigrants and migrants that are US-bound through the United States Refugee Admission Program and in the United States. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be September 30, 2023, through September 29, 2028.

FOR FURTHER INFORMATION CONTACT:

Travis Myers, Division of Global Migration and Quarantine, Immigrant, Refugee, and Migrant Health Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, MS H16–4, Atlanta, GA 30329, Telephone: 770–530–6449, Email: QRK4@cdc.gov.

SUPPLEMENTARY INFORMATION: The single-source award will establish surveillance for infectious diseases in new locations, evaluate the health status of U.S. bound migrants for the purposes of informing and improving U.S. policy regarding overseas and post-arrival health assessment with physicians and prevent the importation and spread of infectious disease into the United States due to a global decrease in routine immunization coverage and an increase in vaccine-preventable diseases outbreaks.

International Organization of Migration is in a unique position to conduct this work, as it carries out the aims of the program due to its work supporting screening activities of U.S. bound populations with all US Panel Physicians. IOM is an international and intergovernmental organization that has the technical and administrative capacity to conduct health assessment activities to support diseases.

Summary of the Award

Recipient: International Organization of Migration (IOM).

Purpose of the Award: The purpose of this award is to support activities to prevent and control efforts for infectious diseases, including vaccine-preventable disease, in U.S.-bound refugee populations, as well as U.S.-bound immigrant, non-immigrant visa (NIV) applicants, parolees and other migrant categories (from hereto called U.S.-bound migrants) worldwide.

Amount of Award: \$1,000,000 in Federal Fiscal Year (FFY) 2023 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under the Public Health Service Act, sections 307 and 317(k)(1) [42 U.S.C. 2421 and 247b(k)(1)].

Period of Performance: September 30, 2023, through September 29, 2028.

Dated: April 21, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–08790 Filed 4–25–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Single-Source Cooperative Agreement To Fund United Way of Middle Tennessee Greater Nashville dba United Way of Greater Nashville

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$4,000,000, for one-year funding period to United Way of Middle Tennessee dba United Way of Greater Nashville. The award will fund a community-based organization (CBO) to expand the implementation of comprehensive high-impact community-based HIV prevention programs in Tennessee.

DATES: The period for this award will be June 1, 2023 through May 31, 2024.

FOR FURTHER INFORMATION CONTACT: Erica K. Dunbar, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, MS US8–3, Atlanta, GA 30329–4027, Telephone: 404–639–6048, Email: CBOFOA@cdc.gov.

SUPPLEMENTARY INFORMATION: This single-source award will: (1) complement existing programs, such as the Ryan White program and other HHS programs, in the local jurisdictions; and (2) address gaps in HIV prevention services throughout the state of Tennessee via direct funding of the United Way of Middle TN dba United Way of Greater Nashville (UWGN) and indirect funding of CBOs throughout Tennessee. Through this NOFO, a 1-year cooperative agreement will be awarded to ensure a continuity of services, address gaps in services, and enhance CBOs' capacity to implement HIV prevention strategies and activities.

United Way of Middle TN dba United Way of Greater Nashville (UWGN) is in a unique position to conduct this work, as it has successfully served as the fiscal

agent and program manager for the CDC HIV prevention and Ending the HIV Epidemic (EHE) programs funds awarded to Tennessee. UWGN has a proven track record of managing the grants, as well as sub-grantee relationships. Further, CBOs are uniquely positioned to complement and extend the reach of HIV prevention efforts implemented by state and local health departments. They support the optimization of services across public, private, and other community-based organizations to achieve objectives of increased identification of HIV diagnoses, referral for pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP) services, earlier entry to HIV care, and increased consistency of care.

Summary of the Awardee

Recipient: United Way of Middle Tennessee dba United Way of Greater Nashville (UWGN).

Purpose of the Award: The purpose of this award is to enhance the capacity of CBOs, through new and continued funding relationships, to implement integrated HIV programs, that complement programs such as the Ryan White program and other HHS programs, within local health department jurisdictions throughout the State of Tennessee.

Amount of Award: \$4,000,000 in Federal Fiscal Year (FFY) 2023 funds, with a total estimated \$4,000,000 for the one-year period of performance, subject to availability of funds.

Authority: This program is authorized under Sections 301 and 318(a) of the Public Health Service Act; 42 U.S.C. 241 and 247c, as amended.

Period of Performance: June 1, 2023 through May 31, 2024.

Dated: April 21, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–08791 Filed 4–25–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).

Date: May 19, 2023.

Time: 11:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G58, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Anuja Mathew, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G58, Rockville, MD 20852, 301-761-6911, anuja.mathew@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 20, 2023.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-08778 Filed 4-25-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Ancillary Studies to the IBD Genetics Consortium.

Date: June 20, 2023.

Time: 12:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Maria E. Davila-Bloom, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7017, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7637, davila-bloom@extra.nidDK.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: April 20, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-08748 Filed 4-25-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; Clinical trials for age-related conditions affecting mobility.

Date: June 6, 2023.

Time: 11:00 a.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Maurizio Grimaldi, M.D., Ph.D., Scientific Review Officer, National

Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Room 2C218, Bethesda, MD 20892, 301-496-9374, grimaldim2@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: April 20, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-08747 Filed 4-25-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed).

Date: May 11, 2023.

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Richard G. Kostriken, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20852, 240-669-2075, richard.kostriken@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)